Related Experiment Video
Updated: Jan 17, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
State-of-the-Art Review: Hepatitis C
Vincent Lo Re1, Debika Bhattacharya2, Jennifer C Price3
1Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
None:
Hepatitis C virus (HCV) infection remains a major cause of chronic liver disease and premature mortality worldwide. The World Health Organization and US Department of Health and Human Services have committed to eliminating HCV infection as a major public health threat by 2030, as defined by a 90% reduction in incidence of new HCV infections and 65% reduction in mortality from a 2015 baseline. To help to achieve HCV elimination, it will be necessary to increase HCV screening and increase uptake of HCV treatment, particularly within primary care, correctional, and substance use treatment settings. In this review, we provide strategies for healthcare providers to implement in their practice to enhance patients' completion of the steps of the HCV care cascade. Improving successful completion of each step of the cascade will help alleviate the burden of HCV infection and make the 2030 HCV elimination goals a reality.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Retrovirus Life Cycles
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

